Sign in to view content

BiWeekly Anti-VEGF Dosing for Chronic Refractory Neovascular Age-Related Macular Degeneration Unresponsive to Standard Monthly Dosing

Eric W Schneider, MD

Video
Published 2019

Related

Retinal Nonperfusion and Anti-VEGF Therapy in Diabetic Retinopathy: What We Know and What We Don’t Know
Dante Joseph Pieramici, MD
Updates from the Field
2017
Novel Vascular Endothelial Growth-Factor A (VEGF-A) and Angiopoietin-2 (Ang-2) Bispecific Protein, RO-634, in Comparison to Aflibercept
Mark R. Barakat, MD
Annual Meeting Talks
2022
Prognostic Value of Subretinal Hyperreflective Material
Russell Pokroy, MD
Updates from the Field
2017

Category: AMD-Neovascular

See more